BioCentury | Dec 18, 2020
Product Development

Next-generation checkpoints acting on NK and T cells: Data Byte

Following the early success of anti-TIGIT mAbs in clinical development this year, interest in next-generation checkpoints has been on the rise, and there’s reason to believe that checkpoints expressed on both T cells and NK...
BioCentury | Dec 17, 2020

GSK adds to next-generation checkpoint pipeline with Surface deal

GlaxoSmithKline’s $85 million deal with Surface Oncology caps off a big month for NK cell technologies and adds PVRIG to the growing list of NK cell checkpoint targets entering pharma pipelines. ...
BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

Immuno-oncology combinations showed mixed results at the first of two virtual annual meetings this year of the American Association for Cancer Research, with PD-L1 inhibitor Tecentriq atezolizumab reporting two negative readouts and uninspiring monotherapy data...
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

As the race continues for the next big checkpoint target after PD-1, three candidates are pulling ahead. BioCentury has been following the rise and fall of clinical programs against promising checkpoint proteins since the field...
BioCentury | Mar 8, 2019
Company News

Compugen cuts workforce by 35%

Compugen will reduce headcount by 35 (35%), with cuts coming primarily from R&D. Compugen Ltd. (NASDAQ:CGEN) said the moves will extend its cash runway through mid-2020 and allow it to fund an expansion study of...
BioCentury | Oct 12, 2018
Company News

Compugen partners with BMS for Phase I combo trial of its first-in-class checkpoint inhibitor

Compugen Ltd. (NASDAQ:CGEN) partnered with Bristol-Myers Squibb Co. (NYSE:BMY) to evaluate its first-in-class mAb COM701 plus BMS's anti-PD-1 mAb Opdivo nivolumab for advanced solid tumors. COM701 targets new checkpoint target poliovirus receptor related immunoglobulin domain...
BioCentury | Aug 24, 2018
Targets & Mechanisms

Computing checkpoints

After 25 years as a discovery company, Compugen Ltd. is about to enter the clinic for the first time with a first-in-class mAb against a new checkpoint target. The target’s expression on adaptive immune cells,...
BioCentury | Mar 31, 2017
Targets & Mechanisms

Cells on the rise

This year’s meeting of the American Association for Cancer Research (AACR) will keep the spotlight on immuno-oncology, where preclinical science is continuing to expand the use of different types of innate and adaptive immune cells...
BioCentury | May 28, 2015
Distillery Therapeutics

Therapeutics: Clostridium difficile toxin B (TcdB); poliovirus receptor-related 3 (PVRL3)

Infectious disease INDICATION: Clostridium Cell culture studies suggest inhibiting the TcdB- PVRL3 interaction could help treat Clostridium difficile infection. In a human colon epithelial cell line treated with TcdB , PVRL3 knockout increased cell survival compared...
BioCentury | Jun 6, 2013
Distillery Therapeutics

Indication: Cancer

...status Publication and contact information Cancer Cancer Poliovirus receptor-related 4 (PVRL4) In vitro and mouse studies suggest inhibiting PVRL4...
...anchorage-independent growth identified PVRL4 as a top candidate. In a series of human cell lines, PVRL4...
...breast cancer, small hairpin RNA knockdown of PVRL4 or treatment with a mAb that disrupts PVRL4-mediated...
Items per page:
1 - 10 of 10